Skip to main content
logo
Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
0.3731
+0.0111 (3.07%)
Oct 15, 2026, 4:00 PM EDT - Market closed

Heron Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
151.18154.9144.29127.04107.6786.35
Revenue Growth
0.99%7.36%13.57%17.99%24.70%-2.59%
Gross Profit
93.63101.1388.9526.81-25.71-89.3
Operating Income
-10.86-2.54-11.53-93.02-169.26-216.43
Net Income
-34.05-20.2-13.58-110.56-182.02-220.68
Earnings Per Share
-0.18-0.12-0.09-0.80-1.67-2.24
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
42.6646.6359.2880.4184.85157.58
Total Debt
148.35140.64177.76179.63157.48159.5
Net Cash (Debt)
-105.69-94.01-118.48-99.22-72.63-1.92
Net Cash Growth
------
Net Cash Per Share
-0.57-0.56-0.78-0.72-0.67-0.02

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-11.61-27.59-22.53-58.79-146.91-203.35
Capital Expenditures
-0.53-0.32-1.71-1.55-1.83-3.02
Free Cash Flow
-12.14-27.91-24.24-60.33-148.74-206.38
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
61.93%65.28%61.65%21.10%-23.87%-103.42%
Operating Margin
-7.19%-1.64%-7.99%-73.22%-157.20%-250.65%
Pretax Margin
-22.52%-13.04%-9.41%-87.02%-169.05%-255.58%
Profit Margin
-22.52%-13.04%-9.41%-87.02%-169.05%-255.58%
FCF Margin
-8.03%-18.02%-16.80%-47.49%-138.14%-239.01%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
-209.09----
PS Ratio
0.451.541.612.012.7610.78